Literature DB >> 20140007

Epigallocatechin-3-gallate (EGCG) attenuates inflammation in MRL/lpr mouse mesangial cells.

Abigail Peairs1, Rujuan Dai, Lu Gan, Samuel Shimp, M Nichole Rylander, Liwu Li, Christopher M Reilly.   

Abstract

Epigallocatechin-3-gallate (EGCG), a bioactive component of green tea, has been reported to exert anti-inflammatory effects on immune cells. EGCG is also shown to activate the metabolic regulator, adenosine 5'-monophosphate-activated protein kinase (AMPK). Reports have also indicated that EGCG inhibits the immune-stimulated phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway. The PI3K/Akt/mTOR pathway has been implicated in mesangial cell activation in lupus. Mesangial cells from MRL/lpr lupus-like mice are hyper-responsive to immune stimulation and overproduce nitric oxide (NO) and other inflammatory mediators when stimulated. In our current studies, we sought to determine the mechanism by which EGCG attenuates immune-induced expression of pro-inflammatory mediators. Cultured mesangial cells from MRL/lpr mice were pre-treated with various concentrations of EGCG and stimulated with lipopolysaccharide (LPS)/interferon (IFN)-gamma. EGCG activated AMPK and blocked LPS/IFN-gamma-induced inflammatory mediator production (iNOS expression, supernatant NO and interleukin-6). Interestingly, EGCG attenuated inflammation during AMPK inhibition indicating that the anti-inflammatory effect of EGCG may be partially independent of AMPK activation. Furthermore, we found that EGCG effectively inhibited the immune-stimulated PI3K/Akt/mTOR pathway independently of AMPK, by decreasing phosphorylation of Akt, suggesting an alternate mechanism for EGCG-mediated anti-inflammatory action in mesangial cells. Taken together, these studies show that EGCG attenuated inflammation in MRL/lpr mouse mesangial cells via the PI3K/Akt/mTOR pathway. Our findings suggest a potential therapeutic role for the use of EGCG to regulate inflammation and control autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20140007      PMCID: PMC4001894          DOI: 10.1038/cmi.2010.1

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  78 in total

1.  Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase.

Authors:  Christopher M Reilly; Libby W Farrelly; Dana Viti; Shakisha T Redmond; Florence Hutchison; Phil Ruiz; Pam Manning; Jane Connor; Gary S Gilkeson
Journal:  Kidney Int       Date:  2002-03       Impact factor: 10.612

2.  Prostaglandin J(2) inhibition of mesangial cell iNOS expression.

Authors:  C M Reilly; J C Oates; J Sudian; M B Crosby; P V Halushka; G S Gilkeson
Journal:  Clin Immunol       Date:  2001-03       Impact factor: 3.969

3.  Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo.

Authors:  L R Borlado; C Redondo; B Alvarez; C Jimenez; L M Criado; J Flores; M A Marcos; C Martinez-A; D Balomenos; A C Carrera
Journal:  FASEB J       Date:  2000-05       Impact factor: 5.191

4.  Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression.

Authors:  R Salcedo; M L Ponce; H A Young; K Wasserman; J M Ward; H K Kleinman; J J Oppenheim; W J Murphy
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

5.  Widespread expression of inducible NOS and citrulline in lupus nephritis tissues.

Authors:  J J Bollain-y-Goytia; R Ramírez-Sandoval; L Daza; E Esparza; O Barbosa; D Ramirez; G Pacheco-Tovar; E Avalos-Diaz; C Rodríguez-Padilla; R Herrera-Esparza
Journal:  Inflamm Res       Date:  2009-02       Impact factor: 4.575

6.  Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype.

Authors:  Duygu Sag; David Carling; Robert D Stout; Jill Suttles
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

7.  A novel transcript of mouse interleukin-20 receptor acts on glomerular mesangial cells as an aggravating factor in lupus nephritis.

Authors:  C-C Wei; M-S Chang
Journal:  Genes Immun       Date:  2008-09-04       Impact factor: 2.676

Review 8.  The role of nuclear factor-kappaB in the development of autoimmune diseases: a link between genes and environment.

Authors:  Alina Kuryłowicz; Janusz Nauman
Journal:  Acta Biochim Pol       Date:  2008-12-16       Impact factor: 2.149

9.  Withaferin A inhibits iNOS expression and nitric oxide production by Akt inactivation and down-regulating LPS-induced activity of NF-kappaB in RAW 264.7 cells.

Authors:  Jung Hwa Oh; Tae-Jin Lee; Jong-Wook Park; Taeg Kyu Kwon
Journal:  Eur J Pharmacol       Date:  2008-09-24       Impact factor: 4.432

10.  The anti-inflammatory and anti-cancer properties of epigallocatechin-3-gallate are mediated by folate cycle disruption, adenosine release and NF-kappaB suppression.

Authors:  E Navarro-Perán; J Cabezas-Herrera; L Sánchez-Del-Campo; F García-Cánovas; J N Rodríguez-López
Journal:  Inflamm Res       Date:  2008-10       Impact factor: 4.575

View more
  38 in total

1.  HDAC expression and activity is upregulated in diseased lupus-prone mice.

Authors:  Nicole L Regna; Miranda D Vieson; Alexander M Gojmerac; Xin M Luo; David L Caudell; Christopher M Reilly
Journal:  Int Immunopharmacol       Date:  2015-10-21       Impact factor: 4.932

2.  MicroRNA-let-7a expression is increased in the mesangial cells of NZB/W mice and increases IL-6 production in vitro.

Authors:  Cristen B Chafin; Nicole L Regna; Rujuan Dai; David L Caudell; Christopher M Reilly
Journal:  Autoimmunity       Date:  2013-09       Impact factor: 2.815

Review 3.  The Green Tea Polyphenol(-)-epigallocatechin-3-gallate and its beneficial roles in chronic kidney disease.

Authors:  Hui Bao; Ai Peng
Journal:  J Transl Int Med       Date:  2016-09-23

4.  A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemia.

Authors:  Ji Hoon Jung; Miyong Yun; Eun-Jeong Choo; Sun-Hee Kim; Myoung-Seok Jeong; Deok-Beom Jung; Hyemin Lee; Eun-Ok Kim; Nobuo Kato; Bonglee Kim; Sanjay K Srivastava; Kunihiro Kaihatsu; Sung-Hoon Kim
Journal:  Br J Pharmacol       Date:  2015-06-04       Impact factor: 8.739

5.  Effects of epigallocatechin-3-gallate on systemic inflammation-induced cognitive dysfunction in aged rats.

Authors:  Daiki Yamanaka; Takashi Kawano; Atsushi Nishigaki; Bun Aoyama; Hiroki Tateiwa; Marie Shigematsu-Locatelli; Fabricio M Locatelli; Masataka Yokoyama
Journal:  J Anesth       Date:  2017-07-27       Impact factor: 2.078

6.  Epigallocatechin gallate inhibits the growth of MDA-MB-231 breast cancer cells via inactivation of the β-catenin signaling pathway.

Authors:  On-Yu Hong; Eun-Mi Noh; Hye-Yeon Jang; Young-Rae Lee; Byoung Kil Lee; Sung Hoo Jung; Jong-Suk Kim; Hyun Jo Youn
Journal:  Oncol Lett       Date:  2017-05-02       Impact factor: 2.967

7.  A negative feedback regulation of MTORC1 activity by the lysosomal Ca2+ channel MCOLN1 (mucolipin 1) using a CALM (calmodulin)-dependent mechanism.

Authors:  Xue Sun; Yiming Yang; Xi Zoë Zhong; Qi Cao; Xin-Hong Zhu; Xiaojuan Zhu; Xian-Ping Dong
Journal:  Autophagy       Date:  2018-02-20       Impact factor: 16.016

8.  The Protective Effect of Epigallocatechin-3 Gallate on Ischemia/Reperfusion Injury in Isolated Rat Hearts: An ex vivo Approach.

Authors:  Cheng Shi Piao; Do-Sung Kim; Ki-Chan Ha; Hyung-Ryong Kim; Han-Jung Chae; Soo-Wan Chae
Journal:  Korean J Physiol Pharmacol       Date:  2011-10-31       Impact factor: 2.016

Review 9.  T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity.

Authors:  Vaishali R Moulton; George C Tsokos
Journal:  J Clin Invest       Date:  2015-05-11       Impact factor: 14.808

10.  Epigallocatechin-3-gallate attenuates lipopolysaccharide-induced inflammation in human retinal endothelial cells.

Authors:  Hui-Yan Zhang; Jian-Yong Wang; Hang-Ping Yao
Journal:  Int J Ophthalmol       Date:  2014-06-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.